港股异动 | 再鼎医药(9688.HK)首日上市高开9.16%
格隆汇9月28日丨再鼎医药(9688.HK)首日上市开报613.5港元,较发行价562港元涨9.16%,暂成交1.6亿港元,最新总市值527亿港元。公司为一间创新型、立足研发及处于商业阶段的生物制药公司,2018年、2019年收益分别为12.9万、1298.5万美元,普通股股东应占亏损1.39亿、1.95亿美元,每股有形资产净值119.5港元。据悉,公司已于2017年9月在美国纳斯达克上市,本次在香港二次上市拟全球发售1056.405万股,其中香港发售89.8万股,国际发售966.605万股,每手50股,香港公开发售获3.43倍认购;净筹约57.304亿港元,当中46.2%将分配至核心产品的研发工作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.